



Laboratory Medicine in the Era of Disruptive Technology

LMCE 2017 & KSLM 58th Annual Meeting

October 18-20, 2017

Grand Walkerhill Seoul, Korea

www.lmce-kslm.org

Biois Co., Ltd.

Product Highlights

Service (Display)



Admera Health
Who We Are

Advanced molecular diagnostics company
focused on **precision medicine**.



PGxOne™ Plus
Pharmacogenomics Testing to
Predict a Patient's Drug Response



Cardiovascular Test Portfolio
Risk Assessment, Disease Diagnosis and
Treatment for Cardiovascular Diseases



Oncology Test Portfolio
Tumor Profiling to Guide Selection
of Targeted Therapies

To learn more about product portfolio visit
admerahealth.com/products

Biois Co., Ltd. is pleased to introduce the advanced genomic technology of admera health Inc. Admera Health's excellent Pharmacogenomics Test Service Panel is now available to Korean Pharmacogenomics researchers, clinicians, and reagents developers for anticancer drug response and companion diagnostics. Non-invasive cancer tests are designed for early disease detection, treatment guidance, treatment response monitoring, and disease recurrence monitoring. Admera Health is developing multiple non-invasive cancer tests to reduce the need for biopsy collection and other invasive sample collection from patients. Our targeted enrichment system detects tumor DNA from blood or urine with exceptionally high sensitivity and specificity, eliminating time-consuming steps seen with most liquid biopsy analytic methods, enabling rapid turn-around of clinically actionable results to treating physicians. For more information about the Pharmacogenomics test service, Please contact the marketing department of Biois Co., Ltd. Thank you.